Drug Profile
Research programme: biphosphonate-vitamin B6 conjugates - MBC Pharma
Alternative Names: MBC-31; MBC-4Latest Information Update: 01 Mar 2023
Price :
$50
*
At a glance
- Originator MBC Pharma
- Class Anti-infectives
- Mechanism of Action Bone resorption factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Bone disorders; Osteomyelitis
Most Recent Events
- 22 Feb 2023 Preclinical development is ongoing in the US
- 16 Aug 2017 Preclinical development is ongoing in Bone disorders and Osteomyelitis
- 16 Aug 2017 MBC Pharma receives SBIR grant from National Institutes of Health (USA) for biphosphonate-vitamin B6 conjugates development in Bone disorders and Osteomyelitis